Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SRT 2104

Drug Profile

SRT 2104

Alternative Names: GSK-2245840; SRT-2104

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sirtris
  • Developer GlaxoSmithKline
  • Class Antihyperglycaemics; Antipsoriatics; Small molecules
  • Mechanism of Action SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Chronic obstructive pulmonary disease; Inflammation; Muscular atrophy; Plaque psoriasis; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 28 Feb 2013 Sirtris completes a phase Ib trial in Ulcerative colitis in the US (NCT01453491)
  • 01 Dec 2012 Sirtris completes a phase I trial (in volunteers) in Plaque psoriasis in USA (NCT01702493)
  • 18 Oct 2012 Phase-I clinical trials in Plaque Psoriasis (in volunteers) in USA (PO, tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top